You are here

  • Home
  • Archive
  • Volume 81, Issue 11
  • Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial

Citation Tools

Article menu

This article has a correction. Please see:

Rheumatoid arthritis
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Balanescu A, Citera G, Pascual-Ramos V, et al
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
Annals of the Rheumatic Diseases 2022;81:1491-1503.